Kanghui Bullish On Joint Implants Despite Looming Price Cuts; Mindray Undercutting U.S. Competition: China Earnings Roundup (Part 4)
This article was originally published in PharmAsia News
Executive Summary
Regulatory headwinds and price cuts led to a massive slowdown in China’s pharmaceutical industry in Q3, but China’s device makers are still enjoying fast growth.
You may also be interested in...
Kanghui: A New Strategic Opens The Door To Orthopedics In China
China Kanghui has emerged as one of the leaders in China’s orthopedics industry, building a business first on trauma and, more recently, spine. Now, with a pending move into reconstruction, the company is looking to other emerging markets, and eventually the US and Europe.
China's Pilot DRG Reimbursement Systems Indicate Substantial Changes To Hospital Prescription Habits
SHANGHAI - China is experimenting with pilot reimbursement programs that rely on diagnosis related groups (DRG) in cities across the country, looking for ways to reduce medical expenses
China's Top Device Maker Mindray Enters Critical Care Market; Sees Boosts From Color Ultrasound Devices
Despite a negative impact from political unrest in the Middle East, China's leading medical device maker Mindray Medical International is steaming ahead with solid first quarter growth in both international and Chinese domestic markets. That growth was driven largely by a continued stronghold in its low- to mid-end device market, as well as an emerging footprint in the lucrative high-end segment with its color ultrasound devices